stockrowAgilent Technologies, Inc.
A Healthcare Diagnostics & Research
Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024.
- Revenue
- +8.06%
- EPS
- +8.47%
- Free cash flow
- +69.5%
- Total debt
- +8.81%
Quarter to July 2026, against a year earlier
Follow A
Alert me
Agilent Technologies, Inc. (A) EPS (diluted)
Agilent Technologies, Inc.'s EPS (diluted) for fiscal 2025 was $4.57, unchanged from fiscal 2024. Over the twelve months to 31 July 2026 it was $5.08. Over the past ten years it has ranged from $0.97 (fiscal 2018) to $4.57 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 5 consecutive fiscal years. Agilent Technologies, Inc. ranks 12th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $4.57 | 3.16% |
| FY2024 | $4.43 | 5.73% |
| FY2023 | $4.19 | 0.24% |
| FY2022 | $4.18 | 6.09% |
| FY2021 | $3.94 | 71.30% |
| FY2020 | $2.30 | (31.75%) |
| FY2019 | $3.37 | 247.42% |
| FY2018 | $0.97 | (53.81%) |
| FY2017 | $2.10 | 50.00% |
| FY2016 | $1.40 | 17.65% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jul 2026 | $1.28 | 6.67% |
| Apr 2026 | $1.20 | 12.15% |
| Jan 2026 | $1.07 | (30.07%) |
| Oct 2025 | $1.53 | 29.66% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MTD Mettler-Toledo International, Inc. compare | $44.43 |
| IDXX IDEXX Laboratories, Inc. compare | $14.83 |
| LH Labcorp Holdings Inc. compare | $12.19 |
| DGX Quest Diagnostics Incorporated compare | $10.04 |
| IQV IQVIA Holdings Inc. compare | $8.24 |
| ILMN Illumina, Inc. compare | $5.81 |
| A Agilent Technologies, Inc. | $5.08 |
| WAT Waters Corporation compare | $2.33 |
| NTRA Natera, Inc. compare | −$1.14 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on A
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement